Granules India
Granules India Limited, headquartered in Hyderabad, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulations, and over-the-counter (OTC) products. Founded in 1984, the company has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities across India and a strong global presence in markets such as the United States and Europe. Granules India is renowned for its commitment to quality and innovation, offering a diverse range of core products that include paracetamol, ibuprofen, and metformin. The company’s unique approach to integrated manufacturing sets it apart, enabling cost-effective production while maintaining high standards. With a robust market position, Granules India has garnered recognition for its sustainable practices and has received multiple certifications from regulatory bodies, solidifying its reputation as a trusted partner in the pharmaceutical sector.
DitchCarbon Score
How does Granules India's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Granules India's score of 66 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Granules India's reported carbon emissions
In 2024, Granules India reported total greenhouse gas emissions of approximately 56,254,000 kg CO2e for Scope 1 and about 31,632,000 kg CO2e for Scope 2, with a combined total of around 87,886,000 kg CO2e for both scopes. The company has set ambitious climate commitments, aiming to achieve net-zero emissions across its value chain by 2050, in alignment with the Science Based Targets initiative (SBTi) 1.5°C pathway. Granules India has established near-term targets to reduce absolute Scope 1 and 2 emissions by 42% by FY2030, using FY2023 as the baseline. Additionally, the company plans to increase its sourcing of renewable electricity from 0% in FY2023 to 100% by FY2030. For Scope 3 emissions, Granules India also targets a 42% reduction by FY2030. Long-term goals include a significant reduction of 90% in absolute Scope 1 and 2 emissions by FY2050, alongside a similar 90% reduction in Scope 3 emissions. These targets reflect Granules India's commitment to sustainability and its proactive approach to mitigating climate change impacts within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 |
| Scope 3 | 452,270,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Granules India is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
